Medication info
Dapaijisoseobangjeong 10/500 mg (Dapagliflozin, Metformin)

Dapaijisoseobangjeong 10/500 mg (Dapagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
Pink, oval-shaped extended-release film-coated tablet with both sides convex
Packaging
30 tablets/box [(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202301894 · Approved 2023.06.21 · Insurance code 641706490

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. For patients switching from concomitant therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the current doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Use in elderly patients).

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar regulation abnormalities
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes who are using dapagliflozin and metformin in combination. It is especially administered as an adjunct to patients following dietary and exercise therapies. Additionally, it is used for patients having difficulty in blood sugar control and those with cardiovascular disease or risk factors; further information regarding the risk of cardiovascular events should be consulted with a healthcare professional. This medication is safely and effectively used to improve blood sugar levels in type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. For patients switching from concomitant therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the current doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Use in elderly patients).

Precautions

This medication contains two active ingredients for the treatment of diabetes. First, this medication works by preventing the reabsorption of glucose in the kidneys, thus helping to lower blood sugar by excreting glucose in the urine. However, there are several precautions to be aware of when using this medication. First, this medication can rarely cause a serious metabolic disorder called lactic acidosis. This condition can lead to excessive buildup of lactic acid in the body, which can be dangerous; thus, if symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain occur, consult a doctor immediately. Second, when used with other diabetes medications or insulin, hypoglycemia may occur, so careful monitoring of blood sugar changes is necessary. Third, it is safer not to use this medication in patients with poor kidney function or conditions such as dehydration, severe infection, heart problems, or liver dysfunction. Fourth, women who are pregnant or breastfeeding should not take this medication, and if planning to become pregnant, they should consult their doctor. Fifth, this medication can increase urine volume leading to fluid depletion; therefore, patients with dehydration symptoms or low blood pressure should be cautious. Sixth, this medication can increase the risk of genital and urinary tract infections; if symptoms of infection occur, adequate treatment should be sought. Seventh, vitamin B12 levels may decrease, so regular blood tests are recommended for long-term use. Eighth, alcohol consumption may increase the risk of side effects from this medication, so excessive drinking should be avoided. Ninth, if undergoing surgery or testing that involves iodine contrast while taking this medication, it may be necessary to pause taking the medication and check kidney function for a period of time. Lastly, this medication may cause dizziness or symptoms of dehydration; thus, caution is needed when driving or operating machinery. This medication should be taken strictly according to a doctor's prescription and instructions, and any unusual symptoms should be reported to healthcare professionals immediately.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • asthenia
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itching
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • neurogenic hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Pink, oval-shaped extended-release film-coated tablet with both sides convex

Package unit

30 tablets/box [(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.